Challenges in Administration of Corticosteroids for the Treatment of AddisonÃ¢ÂÂs Disease: A Case Study of Fludrocortisone Acetate
Najim A AL-Awwadi1* and Makarim Mohammad Ali Hassan2
1Faculty of pharmacy, Chair man of department of pharmacognosy, University of Thi-Qar, Iraq
2Faculty of pharmacy, Department of basic science, University of Thi-Qar, Iraq
- *Corresponding Author:
- Najim A AL-Awwadi
- Faculty of pharmacy, Chair man of department
of pharmacognosy, University of Thi-Qar, Iraq
- Tel: 00964 7810877994
E-mail: [email protected]
Received date: May 23, 2017; Accepted date: June 21, 2017; Published date: June 28, 2017
Citation: AL-Awwadi NA, Ali Hassan MM (2017) Challenges in Administration of Corticosteroids for the Treatment of Addison’s Disease: A Case Study of Fludrocortisone Acetate. J Bioanal Biomed 9:164-168. doi: 10.4172/1948-593X.1000172
Copyright: © 2017 AL-Awwadi NA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Fludrocortisone is a known corticosteroid used to control the amount of sodium and fluids in body. Fludrocortisone act by decreasing the amount of sodium that is excreted in your urine. It is indicated to take orally and it is recommended not to stop Fludrocortisone treatment without Physician consent as sudden stoppage leads to several moderate to severe adverse effects.
There are several moderate to severe adverse effects reported with treatment of Fludrocortisone including high Blood Pressure (BP), Heart failure, weakness of muscles, changes in mood and low immune system function. Considering this there is need to develop sustained release formulation as microparticles which help to improve patient compliance by reducing dosage frequency which overall help to reduce side effects reported with Fludrocortisone.
The aim of this research is to develop different formulations of Fludrocortisone (FLU) by using various polymers (poly(ε-caprolactone, PLC), Eudragit® RS and Eudragit® RL) and different processes (oil-in-water (O/W) solvent evaporation methods and suspension-in-oil-in-water (S/O/W) evaporation methods). Small poly(ε-caprolactone (PCL)-based microparticles have successfully developed during study which was leading to good efficiency when it was prepared by oil-in-water (O/W) emulsion method with 7.5 mg/ml of FLU.